Your browser doesn't support javascript.
loading
Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease.
Smith, Gordon I; Shankaran, Mahalakshmi; Yoshino, Mihoko; Schweitzer, George G; Chondronikola, Maria; Beals, Joseph W; Okunade, Adewole L; Patterson, Bruce W; Nyangau, Edna; Field, Tyler; Sirlin, Claude B; Talukdar, Saswata; Hellerstein, Marc K; Klein, Samuel.
Afiliação
  • Smith GI; Atkins Center of Excellence in Obesity Medicine, Center for Human Nutrition, John T. Milliken Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Shankaran M; Department of Nutritional Sciences and Toxicology, College of Natural Resources, University of California at Berkeley, Berkeley, California, USA.
  • Yoshino M; Atkins Center of Excellence in Obesity Medicine, Center for Human Nutrition, John T. Milliken Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Schweitzer GG; Atkins Center of Excellence in Obesity Medicine, Center for Human Nutrition, John T. Milliken Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Chondronikola M; Atkins Center of Excellence in Obesity Medicine, Center for Human Nutrition, John T. Milliken Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Beals JW; Atkins Center of Excellence in Obesity Medicine, Center for Human Nutrition, John T. Milliken Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Okunade AL; Atkins Center of Excellence in Obesity Medicine, Center for Human Nutrition, John T. Milliken Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Patterson BW; Atkins Center of Excellence in Obesity Medicine, Center for Human Nutrition, John T. Milliken Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Nyangau E; Department of Nutritional Sciences and Toxicology, College of Natural Resources, University of California at Berkeley, Berkeley, California, USA.
  • Field T; Department of Nutritional Sciences and Toxicology, College of Natural Resources, University of California at Berkeley, Berkeley, California, USA.
  • Sirlin CB; Liver Imaging Group, University of California, San Diego, La Jolla, California, USA.
  • Talukdar S; Merck & Co., San Francisco, California, USA.
  • Hellerstein MK; Department of Nutritional Sciences and Toxicology, College of Natural Resources, University of California at Berkeley, Berkeley, California, USA.
  • Klein S; Atkins Center of Excellence in Obesity Medicine, Center for Human Nutrition, John T. Milliken Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
J Clin Invest ; 130(3): 1453-1460, 2020 03 02.
Article em En | MEDLINE | ID: mdl-31805015
BACKGROUNDAn increase in intrahepatic triglyceride (IHTG) is the hallmark feature of nonalcoholic fatty liver disease (NAFLD) and is decreased by weight loss. Hepatic de novo lipogenesis (DNL) contributes to steatosis in individuals with NAFLD. The physiological factors that stimulate hepatic DNL and the effect of weight loss on hepatic DNL are not clear.METHODSHepatic DNL, 24-hour integrated plasma insulin and glucose concentrations, and both liver and whole-body insulin sensitivity were determined in individuals who were lean (n = 14), obese with normal IHTG content (n = 26), or obese with NAFLD (n = 27). Hepatic DNL was assessed using the deuterated water method corrected for the potential confounding contribution of adipose tissue DNL. Liver and whole-body insulin sensitivity was assessed using the hyperinsulinemic-euglycemic clamp procedure in conjunction with glucose tracer infusion. Six subjects in the obese-NAFLD group were also evaluated before and after a diet-induced weight loss of 10%.RESULTSThe contribution of hepatic DNL to IHTG-palmitate was 11%, 19%, and 38% in the lean, obese, and obese-NAFLD groups, respectively. Hepatic DNL was inversely correlated with hepatic and whole-body insulin sensitivity, but directly correlated with 24-hour plasma glucose and insulin concentrations. Weight loss decreased IHTG content, in conjunction with a decrease in hepatic DNL and 24-hour plasma glucose and insulin concentrations.CONCLUSIONSThese data suggest hepatic DNL is an important regulator of IHTG content and that increases in circulating glucose and insulin stimulate hepatic DNL in individuals with NAFLD. Weight loss decreased IHTG content, at least in part, by decreasing hepatic DNL.TRIAL REGISTRATIONClinicalTrials.gov NCT02706262.FUNDINGThis study was supported by NIH grants DK56341 (Nutrition Obesity Research Center), DK20579 (Diabetes Research Center), DK52574 (Digestive Disease Research Center), and RR024992 (Clinical and Translational Science Award), and by grants from the Academy of Nutrition and Dietetics Foundation, the College of Natural Resources of UCB, and the Pershing Square Foundation.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Resistência à Insulina / Lipogênese / Hepatopatia Gordurosa não Alcoólica / Fígado Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Resistência à Insulina / Lipogênese / Hepatopatia Gordurosa não Alcoólica / Fígado Idioma: En Ano de publicação: 2020 Tipo de documento: Article